PMID- 17383105
OWN - NLM
STAT- MEDLINE
DCOM- 20070815
LR  - 20131121
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 146
IP  - 2
DP  - 2007 May 11
TI  - A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 
      methylenedioxymethamphetamine ("ecstasy").
PG  - 509-14
AB  - The drug 3,4 methylenedioxymethamphetamine (MDMA; ecstasy) has a widely 
      documented ability to increase feelings of love and closeness toward others. The 
      present study investigated whether oxytocin, a neuropeptide involved in 
      affiliative behavior, may play a role in this effect. A moderate (5 mg/kg, i.p.) 
      dose of MDMA increased social interaction in male Wistar rats, primarily by 
      increasing the amount of time rats spent lying adjacent to each other. MDMA (5 
      mg/kg) activated oxytocin-containing neurons in the supraoptic and 
      paraventricular nuclei of the hypothalamus, as shown by Fos immunohistochemistry. 
      MDMA (5 mg/kg i.p.) also increased plasma oxytocin levels and this effect was 
      prevented by pre-treatment with the 5-HT(1A) antagonist 
      N-[2-[4-(2-methyoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide 
      maleate salt (WAY 100,635; 1 mg/kg i.p.). The oxytocin receptor antagonist 
      tocinoic acid (20 microg, i.c.v.) had no effect on social behavior when given 
      alone but significantly attenuated the facilitation of social interaction 
      produced by MDMA (5 mg/kg). The 5-HT(1A) agonist 
      8-hydroxy-2-(di-n-propylamino)-tetraline) (8-OH-DPAT, 0.25 mg/kg, i.p.) increased 
      social behavior in a similar way to MDMA and this effect was also significantly 
      attenuated by tocinoic acid. Taken together, these results suggest that oxytocin 
      release, stimulated by MDMA through 5-HT(1A) receptors, may play a key role in 
      the prosocial effects of MDMA and underlie some of the reinforcing effects of the 
      drug.
FAU - Thompson, M R
AU  - Thompson MR
AD  - School of Psychology, University of Sydney, Griffith Taylor Building (A18), 
      Sydney, NSW, 2006, Australia.
FAU - Callaghan, P D
AU  - Callaghan PD
FAU - Hunt, G E
AU  - Hunt GE
FAU - Cornish, J L
AU  - Cornish JL
FAU - McGregor, I S
AU  - McGregor IS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070323
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hallucinogens)
RN  - 0 (Piperazines)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (Pyridines)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
RN  - 34330-23-9 (tocinoic acid)
RN  - 50-56-6 (Oxytocin)
RN  - 71IH826FEG 
      (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide)
RN  - 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Drug Interactions
MH  - Enzyme Inhibitors/pharmacology
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Oxytocin/analogs & derivatives/pharmacology/*physiology
MH  - Piperazines/pharmacology
MH  - Proto-Oncogene Proteins c-fos/metabolism
MH  - Pyridines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Serotonin, 5-HT1A/*physiology
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin Receptor Agonists/pharmacology
MH  - *Social Behavior
EDAT- 2007/03/27 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/03/27 09:00
PHST- 2007/01/19 00:00 [received]
PHST- 2007/02/15 00:00 [revised]
PHST- 2007/02/15 00:00 [accepted]
PHST- 2007/03/27 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/03/27 09:00 [entrez]
AID - S0306-4522(07)00196-0 [pii]
AID - 10.1016/j.neuroscience.2007.02.032 [doi]
PST - ppublish
SO  - Neuroscience. 2007 May 11;146(2):509-14. doi: 10.1016/j.neuroscience.2007.02.032. 
      Epub 2007 Mar 23.